GLYC (GlycoMimetics) Enterprise Value-to-Revenue Coefficient

Official company branding of GlycoMimetics, Inc. (GLYC)

Due to the failure of leukemia drug trials, GlycoMimetics, Inc. (GLYC) has lost its pricing power and is undergoing restructuring. This EV/Revenue chart illustrates the valuation trend, where the current metric is . Business stability depends on the success of uproleselan and the inflow of capital to cover Phase 3 risks, while molecule discovery relies on the robotic analysis of biochemical reactions.

GlycoMimetics Inc. (GLYC): EV/Sales Multiple from 07/04/2022 to 11/20/2026

Financial and market metric breakdowns for GlycoMimetics Corp (GLYC)

- price and consensus price forecast:
- business market valuation indicators:
Fundamental company valuation:GlycoMimetics Inc. GLYC
Product sample of GlycoMimetics Inc.

Investors must monitor long-term risks by evaluating the enterprise value-to-revenue ratio, calculated as the ratio of total business capitalization to sales, excluding leverage. An upward trend on this chart signals inflated expectations, which is critical for GlycoMimetics, Inc. (GLYC), as its valuation depends on the successful integration of innovative glycomimetics into leukemia therapy standards.